Japan· JP-2119402P1143
ドパミン塩酸塩
A dopamine product containing ドパミン塩酸塩, registered in Japan by ヴィアトリス・ヘルスケア, on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Dopamine is registered in 16 of 19 countries.
Countries holding a registration under ATC C01CA04 (dopamine), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 9 of them publish a price we can compare per daily dose
Dopamine · ATC C01CA04
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- United Kingdom
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ドパミン塩酸塩
- Manufacturer
- ヴィアトリス・ヘルスケア
- Country
- Japan (JP)
- ATC code
- C01CA04
- ATC class
- Dopamine
- Defined daily dose
- 0.5 g, P
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
103 interactions on record for dopamine.
Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Dopamine · interactions on record
103 records
- 9 severe
- 91 moderate
- 3 minor
Most severe, free to view
- ProcarbazineL01XB01severe
- OzanimodL04AA38severe
- OzanimodL04AE02severe
- CocaineN01BC01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under C01CA04
Dopamine, as other registers publish it.
- FinlandAbbodopHospira Enterprises BV
- FinlandAbbodopHospira Enterprises BV
- NorwayDopaminEvolan Pharma AB
- GermanyDopamin FreseniusFresenius Kabi Deutschland Gmbh
- SpainDOPAMINA BASI 40 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION EFGLaboratorios Basi Industria Farmaceutica S.A.
- SpainDOPAMINA GRIFOLS 200 mg SOLUCIÓN INYECTABLELaboratorios Grifols S.A.
- United StatesDopamineNewton Laboratories, Inc.
- United StatesDopamineDeseret Biologicals, Inc.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fe11952b-8fae-40de-bcf7-d928711db1f7 GET /v1/drugs/fe11952b-8fae-40de-bcf7-d928711db1f7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "０．１％２００ｍＬ１袋",
"marks": "局",
"source": "mhlw",
"remarks": null,
"yj_code": "2119402P1143",
"category": "注射薬",
"price_yen": 1362,
"generic_name": "ドパミン塩酸塩",
"product_name_jp": null,
"therapeutic_class": "2119",
"transitional_expiry": null
}See everything about dopamine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.